Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC35511 structure
    GC35511BI-0252
    CAS: 1818291-27-8

    BI-0252 是一种具有口服活性,选择性的 MDM2-p53 抑制剂,IC50 值为 4 nM。 BI-0252 可诱导异种移植小鼠 SJSA-1 的所有动物肿瘤消退,同时诱导肿瘤蛋白p53 (TP53) 靶基因和凋亡标志物。

  • GC35523 structure
    GC35523Bioymifi
    CAS: 1420071-30-2
    纯度: >98.00%

    A DR5 agonist

  • GC35530 structure
    GC35530BJE6-106
    CAS: 1564249-38-2

    BJE6-106 (B106) 是一种有效的选择性 PKCδ 抑制剂,IC50 值为 0.05 μM,BJE6-106 (B106) 靶向 PKCδ 的选择性是 PKC 同工酶 PKCα 的 1000倍 (IC50=50 μM)。BJE6-106 (B106) 可以诱导 caspase 依耐性细胞凋亡 (apoptosis)。BJE6-106 (B106) 具有肿瘤特异性作用。

  • GC35554 structure
    GC35554Brevilin A
    CAS: 16503-32-5
    纯度: >98.00%

    A sesquiterpene lactone with anticancer activity

  • GC35555 structure
    GC35555Britannin
    CAS: 33627-28-0
    纯度: >99.50%

    Britannin,分离于 Inula aucheriana,是倍半萜内酯。Britannin 通过激活由 ROS 调节的 AMPK 来诱导肝癌细胞凋亡和自噬。Britannin 具有抗增殖和抗炎活性。

  • GC35559 structure
    GC35559Bruceine D
    CAS: 21499-66-1
    纯度: >98.00%

    Bruceine D, isolated from Brucea javanica (L.) Merr. (Simaroubaceae), shows antineoplastic properties in various human cancers including pancreas, breast, lung, blood, bone, and liver. Bruceine D induces apoptosis in human chronic myeloid leukemia K562 cells via mitochondrial pathway.

  • GC35598 structure
    GC35598Camellianin A
    CAS: 109232-77-1

    Camellianin A 是 A. nitida 叶中主要的黄酮类化合物,具有抗癌活性和抗血管紧张素转换酶 (ACE) 活性。Camellianin A 能抑制人 Hep G2 和 MCF-7 细胞的增殖,诱导细胞 G0/G1 期停滞。

  • GC35612 structure
    GC35612Carvacrol
    CAS: 499-75-2
    纯度: >99.50%

    Carvacrol 是一种具有口服活性的单萜酚。

  • GC35629 structure
    GC35629CDDO-dhTFEA
    CAS: 1191265-33-4
    纯度: >99.50%

    CDDO-dhTFEA (RTA dh404) 是一种合成的齐墩果烷三萜化合物,有效激活 Nrf2 并抑制促炎转录因子 NF-κB。 CDDO-dhTFEA 可以恢复高血压 (MAP),增加 Nrf2 及其靶基因的表达,减弱 NF-κB 的活化和转化生长因子-β 途径,并减少慢性肾病 (CKD) 大鼠的肾小球硬化,间质纤维化和炎症。

  • GC35630 structure
    GC35630CDDO-EA
    CAS: 932730-51-3
    纯度: >98.00%

    CDDO-EA 是一种 NF-E2 相关因子 2 /抗氧化反应元件 (Nrf2/ARE) 激活剂。

  • GC35636 structure
    GC35636CDK9-IN-7
    CAS: 2369981-71-3
    纯度: >99.50%

    CDK9-IN-7 (compound 21e) 是一种高效选择性的,具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干度的特性。

  • GC35668 structure
    GC35668CG-200745
    CAS: 936221-33-9

    CG-200745 (CG-200745) 是一种具有口服活性的强效 pan-HDAC 抑制剂,其异羟肟酸部分可与催化袋底部的锌结合。 CG-200745 抑制组蛋白 H3 和微管蛋白的去乙酰化。 CG-200745 诱导 p53 的积累,促进 p53 依赖性反式激活,并增强 MDM2 和 p21 (Waf1/Cip1) 蛋白的表达。 CG-200745 增强了吉西他滨耐药细胞对吉西他滨和 5-氟尿嘧啶 (5-FU;) 的敏感性。 CG-200745 诱导细胞凋亡并具有抗肿瘤作用。

  • GC35682 structure
    GC35682CHMFL-ABL/KIT-155
    CAS: 2081093-21-0

    CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) 是一种高效的,具有口服活性的 type II ABL/c-KIT 双激酶抑制剂 (IC50 分别为 46 nM 和 75 nM),对 BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM), PDGFRβ (IC50=80 nM) 激酶也具有明显的抑制活性。CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) 阻止细胞周期进展和诱导细胞凋亡。

  • GC35703 structure
    GC35703Citicoline
    CAS: 987-78-0
    纯度: >99.50%

    An intermediate in the synthesis of phosphatidylcholine

  • GC35747 structure
    GC35747Crebanine
    CAS: 25127-29-1
    纯度: >99.50%

    An aporphine alkaloid with diverse biological activities

  • GC35750 structure
    GC35750CRT0066101 dihydrochloride
    CAS: 1883545-60-5
    纯度: >98.00%

    CRT0066101 dihydrochloride is a small molecule PKD family specific inhibitor which specifically blocks PKD1/2 activity and does not suppress PKCα/PKCβ/PKCε activity in multiple.

  • GC35758 structure
    GC35758Cucurbitacin IIa
    CAS: 58546-34-2
    纯度: >99.00%

    Curcurbitacin IIA (Cucurbitacin Iia, CuIIa, Hemslecin A, Dihydrocucurbitacin Q1) is the major active component of the Helmseya amabilis root and is known to have antiviral and anti-inflammatory effects.

  • GC35812 structure
    GC35812Dasatinib hydrochloride
    CAS: 854001-07-3
    纯度: >98.50% / >99.00%

    An inhibitor of Abl and Src

  • GC35829 structure
    GC35829Dehydroaltenusin
    CAS: 31186-13-7

    Dehydroaltenusin 脱氢阿霉素是真核DNA 聚合酶 α (DNA polymerase α) 的小分子选择性抑制剂,一种由真菌产生的抗生素,其 IC50值为 0.68 μM。 Dehydroaltenusin 对哺乳动物 polα 活性的抑制作用模式对 DNA 模板引物 (Ki=0.23 μM) 是竞争性的,对 2'-脱氧核糖核苷 5'-三磷酸底物是非竞争性的 (Ki=0.18 μM)。Dehydroaltenusin 在 S 期阻止癌细胞周期并触发凋亡 apoptosis。Dehydroaltenusin 在体内具有抗人类腺癌肿瘤的抗肿瘤活性。

  • GC35834 structure
    GC35834Dehydroeffusol
    CAS: 137319-34-7

    Dehydroeffusol 是一种来自草药 Juncus effuses 的菲。Dehydroeffusol 通过选择性诱导肿瘤抑制性内质网应激和中度凋亡来抑制胃癌细胞生长和致瘤性。Dehydroeffusol 显示出非常低的毒性。

  • GC35859 structure
    GC35859Diazepinomicin
    CAS: 733035-26-2

    Diazepinomicin (TLN-4601) 是Micromonospora sp 的次生代谢产物,可抑制EGF 诱导的 Ras-ERK MAPK 信号通路,可诱导凋亡。是一种可用于 K-Ras 突变型的抗肿瘤药物。

  • GC35882 structure
    GC35882dMCL1-2
    CAS: 2351218-88-5

    dMCL1-2 是一种基于 PROTAC 技术的,高效、选择性的 MCL1 降解剂,结合 MCL1 的 KD 值为 30 nM。dMCL1-2 通过降解 MCL1 激活细胞凋亡。

  • GC35898 structure
    GC35898Dracorhodin perchlorate
    CAS: 125536-25-6
    纯度: >98.00%

    A pro-apoptotic compound

  • GC35908 structure
    GC35908Duocarmycin A
    CAS: 118292-34-5

    Duocarmycin A 是众所周知的抗肿瘤抗生素之一,可有效地使 DNA 中富含 AT 的序列 3' 末端的腺嘌呤 N3 烷基化。Duocarmycin A 作为一种化学治疗剂,通常导致 HLC-2 细胞凋亡,包括染色质浓缩,DNA 直方图模式中的亚 G1 积累,以及procaspase-3 和 9 水平的降低。